The Joint Venture with Novartis is a mess - Mitarbeiter (anonym) bei GSK: Mitarbeiterbewertung

3,0
9. Juni 2015
Mitarbeiter (anonym)
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Compensation, Big Brands, OTC Switch capability

Kontras

The Joint Venture with Novartis is all about cutting costs. The new GSK will be way too lean. I fear the GSK I know and love will be long gone in a few months. The transition will be long and difficult. Many things will fall trought the cracks and GSK will be less customer focused and even more focused on saving a buck. The poor performance of Big Pharma has made life difficult for Consumer Healthcare as we need to help the broader company keep the dividends high.

Mehr Bewertungen zu GSK entdecken

5,0
12. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Can't emphasize enough how approachable, non-judgmental, and supportive the team is, both managers and colleagues. Everyone genuinely cares about your holistic professional development and growth.

Kontras

This may seem unrealistic, but I genuinely did not have a single negative experience during my time here.

5,0
5. Juli 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Good people good atmosphere feel valued as an employee.

Kontras

None that I can think of. Smooth sailing.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle